Annual CFF
$5.28 M
-$67.05 M-92.69%
31 December 2022
Summary:
Better Therapeutics annual cash flow from financing activities is currently $5.28 million, with the most recent change of -$67.05 million (-92.69%) on 31 December 2022. During the last 3 years, it has fallen by -$2.16 million (-29.03%). BTTX annual CFF is now -92.69% below its all-time high of $72.33 million, reached on 31 December 2021.BTTX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFF
$6.28 M
+$561.00 K+9.81%
30 September 2023
Summary:
Better Therapeutics quarterly cash flow from financing activities is currently $6.28 million, with the most recent change of +$561.00 thousand (+9.81%) on 30 September 2023. BTTX quarterly CFF is now -88.30% below its all-time high of $53.66 million, reached on 31 December 2021.BTTX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFF
$11.69 M
+$6.27 M+115.72%
30 September 2023
Summary:
Better Therapeutics TTM cash flow from financing activities is currently $11.69 million, with the most recent change of +$6.27 million (+115.72%) on 30 September 2023. BTTX TTM CFF is now -83.83% below its all-time high of $72.33 million, reached on 31 December 2021.BTTX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
BTTX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | - | - |
| 3 y3 years | -29.0% | -21.5% | -37.4% |
| 5 y5 years | - | - | - |
BTTX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -92.7% | at low | -88.3% | +1543.5% | -83.8% | +141.2% |
| 5 y | 5 years | -92.7% | at low | -88.3% | +1543.5% | -83.8% | +150.1% |
| alltime | all time | -92.7% | at low | -88.3% | +1543.5% | -83.8% | +150.1% |
Better Therapeutics Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2023 | - | $6.28 M(+9.8%) | $11.69 M(+115.7%) |
| June 2023 | - | $5.72 M(-1414.5%) | $5.42 M(+11.8%) |
| Mar 2023 | - | -$435.00 K(-429.5%) | $4.85 M(-8.3%) |
| Dec 2022 | $5.28 M | $132.00 K(+2100.0%) | $5.28 M(-91.0%) |
| Sept 2022 | - | $6000.00(-99.9%) | $58.81 M(-12.0%) |
| June 2022 | - | $5.14 M(>+9900.0%) | $66.80 M(-1.3%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2022 | - | $1000.00(-100.0%) | $67.66 M(-6.5%) |
| Dec 2021 | $72.33 M(+871.6%) | $53.66 M(+570.7%) | $72.33 M(+287.3%) |
| Sept 2021 | - | $8.00 M(+33.3%) | $18.68 M(+74.9%) |
| June 2021 | - | $6.00 M(+28.3%) | $10.68 M(+128.3%) |
| Mar 2021 | - | $4.67 M | $4.67 M |
| Dec 2020 | $7.45 M(-14.4%) | - | - |
| Dec 2019 | $8.70 M | - | - |
FAQ
- What is Better Therapeutics annual cash flow from financing activities?
- What is the all time high annual CFF for Better Therapeutics?
- What is Better Therapeutics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Better Therapeutics?
- What is Better Therapeutics TTM cash flow from financing activities?
- What is the all time high TTM CFF for Better Therapeutics?
What is Better Therapeutics annual cash flow from financing activities?
The current annual CFF of BTTX is $5.28 M
What is the all time high annual CFF for Better Therapeutics?
Better Therapeutics all-time high annual cash flow from financing activities is $72.33 M
What is Better Therapeutics quarterly cash flow from financing activities?
The current quarterly CFF of BTTX is $6.28 M
What is the all time high quarterly CFF for Better Therapeutics?
Better Therapeutics all-time high quarterly cash flow from financing activities is $53.66 M
What is Better Therapeutics TTM cash flow from financing activities?
The current TTM CFF of BTTX is $11.69 M
What is the all time high TTM CFF for Better Therapeutics?
Better Therapeutics all-time high TTM cash flow from financing activities is $72.33 M